.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD03_TixagevimabAndCilgavimab.TixagevimabAndCilgavimab .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD03_TixagevimabAndCilgavimab.TixagevimabAndCilgavimab| name: | TixagevimabAndCilgavimab |
| ATC code: | J06BD03 | route: | intramuscular |
| n-compartments | 2 |
Tixagevimab and cilgavimab are two recombinant human monoclonal antibodies targeting the SARS-CoV-2 spike protein, used in combination as pre-exposure prophylaxis and treatment for COVID-19. This combination is approved by regulatory agencies such as the FDA and EMA for certain populations at increased risk of inadequate response to vaccination or exposure.
Pharmacokinetic parameters are based on healthy adult volunteers and immunocompromised patients receiving a single intramuscular administration.
Clegg, LE, et al., & Någård, M (2024). Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19. Antimicrobial agents and chemotherapy 68(5) e0158723–None. DOI:10.1128/aac.01587-23 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38534112